Phase I study of oral capecitabine (Xeloda) as a radiation enhancer in locally unresectable, residual, or recurrent colorectal cancer localized in the pelvis

Trial Profile

Phase I study of oral capecitabine (Xeloda) as a radiation enhancer in locally unresectable, residual, or recurrent colorectal cancer localized in the pelvis

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2015

At a glance

  • Drugs Capecitabine (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 13 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top